Drug intelligence / Profile preview

deligoparin

Development stage: Phase 3
Lead developer: Opocrin
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Intravenous

Overview

Deligoparin (deligoparin sodium, code name OP 2000) is an ultra low molecular weight heparin developed as an anticoagulant and antithrombotic agent. It acts primarily as a Factor Xa inhibitor and also inhibits thrombin. Deligoparin was investigated for the treatment of ulcerative colitis and unstable angina pectoris but development was discontinued after reaching phase III clinical trials for ulcerative colitis in the US. The drug was originally developed by Opocrin[1][2]. As a member of the low molecular weight heparins class, it exerts its effect by potentiating antithrombin activity to inhibit clotting factors involved in thrombosis[1].

Other names: deligoparin sodiumOP 2000OP2000OP-2000

Targets

ATIII (Antithrombin III)F10 (Factor Xa)F2 (Thrombin)

Beyond the preview

Go deeper on deligoparin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on deligoparin.

Explore the full profile